Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

July 10, 2020

Study Completion Date

September 23, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

COVID-19 convalescent hyperimmune plasma

Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one

BIOLOGICAL

Non-convalescent fresh frozen plasma (Standard plasma)

Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one

Trial Locations (1)

115682

Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow

All Listed Sponsors
lead

Federal Research Clinical Center of Federal Medical & Biological Agency, Russia

OTHER_GOV

NCT04392414 - Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease | Biotech Hunter | Biotech Hunter